Stockscreener 앱 받기
10.00
2.99%
0.29
시간 외 거래:
9.97
-0.03
-0.30%
전일 마감가:
$9.71
열려 있는:
$9.92
하루 거래량:
176.07K
Relative Volume:
2.93
시가총액:
$276.68M
수익:
-
순이익/손실:
$-28.87M
주가수익비율:
-7.7882
EPS:
-1.284
순현금흐름:
$-16.01M
1주 성능:
+17.65%
1개월 성능:
+30.72%
6개월 성능:
+76.37%
1년 성능:
+11.61%
1일 변동 폭
$9.44
$10.00
1주일 범위
$8.42
$10.00
52주 변동 폭
$5.55
$11.15
Nuvectis Pharma Inc Stock (NVCT) Company Profile
명칭
Nuvectis Pharma Inc
전화
360-837-7232
주소
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Compare NVCT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
10.00 | 268.66M | 0 | -28.87M | -16.01M | -1.284 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-02 | 개시 | Maxim Group | Buy |
| 2025-03-17 | 개시 | Laidlaw | Buy |
| 2022-07-13 | 개시 | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc 주식(NVCT)의 최신 뉴스
Companies Like Nuvectis Pharma (NASDAQ:NVCT) Are In A Position To Invest In Growth - simplywall.st
Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Nuvectis Pharma, Inc. Q1 2026: Net loss $(6.05M), EPS $(0.26) — 10-Q Summary - TradingView
Nuvectis Pharma (NASDAQ: NVCT) posts $6.1M Q1 loss with $25.1M cash - Stock Titan
Nuvectis Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Nuvectis Pharma posts first quarter 2026 financial results and business update - Traders Union
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights - Weekly Voice
Cancer drug developer targets summer data as cash drops to $25.1M - Stock Titan
Insider Stock Buying Reaches US$2.07m On Nuvectis Pharma - Yahoo Finance
NVCT (Nuvectis Pharma) posts narrow Q4 2025 EPS miss, edging down 0.23% in muted investor reaction.Community Momentum Stocks - Newser
Nuvectis Pharma (NVCT) price target decreased by 11.71% to 16.66 - MSN
NVCT Forecast, Price Target & Analyst Ratings | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Nuvectis Pharma (NVCT) Stock: Technical Risk Signals | Q4 2025: Below ExpectationsCommunity Risk Signals - Newser
Nuvectis Pharma (NVCT) Projected to Post Earnings on Tuesday - MarketBeat
Nuvectis Pharma (NASDAQ: NVCT) details 2026 annual meeting and executive pay - Stock Titan
Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - Stock Traders Daily
NVCT (Nuvectis Pharma) posts slight Q4 2025 EPS miss, yet shares edge higher on positive investor sentiment.Earnings Preview - Newser
NVCT Stock Price, Quote & Chart | NUVECTIS PHARMA INC (NASDAQ:NVCT) - ChartMill
Technical Reactions to NVCT Trends in Macro Strategies - Stock Traders Daily
Nuvectis Pharma, Inc. $NVCT Shares Acquired by Iridian Asset Management LLC CT - MarketBeat
Will Nuvectis Pharma (NVCT) Stock Recover Soon | Price at $7.65, Up 1.19%Market Hype - Newser
Trading the Move, Not the Narrative: (NVCT) Edition - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Trading Down 1.7%Here's What Happened - MarketBeat
Nuvectis to present NXP900 data at cancer research meeting By Investing.com - Investing.com South Africa
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting - Investing News Network
Nuvectis Pharma announces upcoming presentations for NXP900 at the 2026 American Association for Cancer Research meeting - marketscreener.com
Nuvectis Pharma schedules NXP900 presentations for 2026 American Association for Cancer Research event - Traders Union
Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire
NVCT Technical Analysis & Stock Price Forecast - Intellectia AI
(NVCT) Volatility Zones as Tactical Triggers - Stock Traders Daily
Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation - Yahoo Finance
Aug Closing: Does Nuvectis Pharma Inc meet Warren Buffetts criteriaEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
NVCT SEC FilingsNuvectis Pharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
NVCT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Price-Driven Insight from (NVCT) for Rule-Based Strategy - Stock Traders Daily
Aug Highlights: Can Nuvectis Pharma Inc maintain its current growth rate2026 Outlook & Reliable Trade Execution Plans - baoquankhu1.vn
Nuvectis Pharma (NASDAQ:NVCT) Shares Up 6.3%Still a Buy? - MarketBeat
Why retail investors pile into Nuvectis Pharma Inc. stock2025 Top Decliners & Risk Controlled Daily Trade Plans - Naître et grandir
(NVCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
NVCT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
NVCT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
NVCT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[EFFECT] Nuvectis Pharma, Inc. SEC Filing - Stock Titan
(NVCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Nuvectis Pharma (NVCT) to Release Quarterly Earnings on Tuesday - Defense World
Is Nuvectis Pharma Inc. stock cheap at current valuationLayoff News & Smart Money Movement Alerts - mfd.ru
Is Nuvectis Pharma Inc. stock a smart buy before Fed meetingJuly 2025 Rallies & Free Accurate Trade Setup Notifications - mfd.ru
What are Nuvectis Pharma Inc.’s growth leversJuly 2025 Macro Moves & Entry Point Confirmation Alerts - mfd.ru
Nuvectis Pharma FY2026 EPS Estimate Cut by HC Wainwright - Defense World
Nuvectis Pharma Files $150 Million Mixed Shelf - marketscreener.com
Analysts Offer Insights on Healthcare Companies: Nuvectis Pharma (NVCT), Tenet Healthcare (THC) and Upstream Bio, Inc. (UPB) - The Globe and Mail
Nuvectis Pharma Inc (NVCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):